Hiteck(300683)

Search documents
海特生物(300683) - 2018 Q3 - 季度财报
2018-10-28 16:00
Financial Performance - Operating revenue for the reporting period was CNY 143,468,981.62, down 23.81% year-on-year[7] - Net profit attributable to shareholders of the listed company decreased by 24.55% to CNY 29,520,230.47[7] - Basic earnings per share were CNY 0.290, a decrease of 23.68% compared to the same period last year[7] - The weighted average return on net assets was 1.79%, down 3.07% year-on-year[7] - Total operating revenue for Q3 2018 was CNY 143,468,981.62, a decrease of 23.7% compared to CNY 188,293,908.47 in the same period last year[34] - The net profit for Q3 2018 was CNY 29,094,656.33, down 25.3% from CNY 38,887,298.70 in Q3 2017[37] - The total profit for Q3 2018 was CNY 32,164,996.85, a decrease of 28.5% from CNY 44,941,897.27 in Q3 2017[36] - The company's total comprehensive income for Q3 2018 was CNY 29,094,656.33, down 25.3% from CNY 38,887,298.70 in Q3 2017[37] - The company's operating income for the third quarter was CNY 408,913,865.89, a decrease from CNY 576,821,164.82 in the previous period[47] - The total profit for the third quarter was CNY 85,878,097.01, down from CNY 125,715,035.99, indicating a decline of about 31.7%[45] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,866,658,130.89, a decrease of 2.21% compared to the end of the previous year[7] - The company's total liabilities decreased by 35.23% to ¥137,552,215.25, mainly due to the settlement of various payables during the reporting period[18] - Total assets decreased to CNY 1,866,333,368.19 from CNY 1,909,913,666.06, reflecting a contraction in the asset base[32] - Total liabilities decreased to CNY 172,029,999.26 from CNY 265,020,639.30, indicating a reduction in financial obligations[32] - The company's equity increased to CNY 1,694,303,368.93 from CNY 1,644,893,026.76, demonstrating growth in shareholder value[33] Shareholder Information - Net assets attributable to shareholders of the listed company increased by 2.75% to CNY 1,681,399,700.58[7] - The total number of common shareholders at the end of the reporting period was 16,972[11] - The largest shareholder, Wuhan Sanjiangyuan Investment Development Co., Ltd., held 38.70% of the shares[11] - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[12] Cash Flow and Investments - The company’s cash flow from operating activities increased by 50.27% to ¥14,284,530.43, primarily due to higher interest income from large fixed deposits[18] - The cash received from investment income increased by 805.19% to ¥25,800,562.90, reflecting a significant rise in investment returns[18] - Total cash inflow from investment activities amounted to 209,375,114.16 CNY, significantly higher than 22,859,634.47 CNY in the previous period[54] - The net cash flow from investment activities was 88,107,914.03 CNY, compared to a negative cash flow of -874,817,928.34 CNY in the previous period[54] - The company received 6,000,000.00 CNY from financing activities, a decrease from 803,373,376.88 CNY in the previous period[55] - The net cash flow from financing activities was -30,866,439.82 CNY, compared to a positive inflow of 803,373,376.88 CNY in the previous period[55] Inventory and Receivables - The company's accounts receivable decreased by 44.08% to ¥18,104,549.72 due to the maturity and settlement of receivables during the reporting period[18] - Inventory increased by 33.26% to ¥29,914,144.63, primarily due to an increase in stock during the reporting period[18] - Accounts receivable decreased to CNY 220,417,515.51 from CNY 266,310,217.45, suggesting improved collection efficiency[31] - Inventory increased to CNY 25,244,763.28 from CNY 20,448,826.41, indicating potential stockpiling for future sales[31] Research and Development - Research and development expenses increased to CNY 9,737,233.09, up from CNY 5,890,258.35, indicating a focus on innovation and new product development[34] - Research and development expenses increased to CNY 9,263,254.98 in Q3 2018, up 62.5% from CNY 5,737,452.59 in the same quarter last year[39] - Research and development expenses for the third quarter were CNY 17,016,408.61, compared to CNY 16,375,858.88 in the previous year, showing an increase of approximately 3.9%[47] Other Financial Metrics - Non-recurring gains and losses totaled CNY 31,281,729.74 for the year-to-date[8] - The company reported an investment income of CNY 12,144,044.86 for Q3 2018, with no comparative figure provided for the previous year[36] - The asset impairment loss for Q3 2018 was CNY 7,069,568.36, compared to CNY 4,976,723.28 in Q3 2017, indicating an increase of 42.1%[36] - The company incurred asset impairment losses of CNY 33,427,763.00, significantly higher than CNY 11,427,395.98 in the previous period, indicating a rise of about 192.5%[47]
海特生物(300683) - 2018 Q2 - 季度财报
2018-08-26 16:00
Financial Performance - Total revenue for the first half of 2018 was CNY 268,582,253.82, a decrease of 30.89% compared to CNY 388,631,216.97 in the same period last year[21]. - Net profit attributable to shareholders was CNY 46,465,576.47, down 33.18% from CNY 69,538,620.03 year-on-year[21]. - The basic earnings per share decreased by 50.00% to CNY 0.45 from CNY 0.90 in the previous year[21]. - The net cash flow from operating activities was CNY 32,997,755.46, a decline of 29.21% compared to CNY 46,611,091.58 in the same period last year[21]. - The company reported a net loss of CNY 31,006,512 for the first half of 2018[139]. - The total profit for the period was CNY 53,713,100.16, down from CNY 80,773,138.72, a decline of approximately 33.5%[124]. - The company reported an operating profit of CNY 53,498,655.45, down from CNY 79,957,523.46, a decrease of about 33.2%[124]. - The company reported a decrease in retained earnings of CNY 1,192,215.73[141]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,856,809,643.91, down 2.72% from CNY 1,908,751,901.97 at the end of the previous year[21]. - Current liabilities totaled CNY 182,164,186.99, a reduction of 28.5% from CNY 254,944,790.77 in the previous period[121]. - Non-current liabilities were CNY 9,426,997.49, slightly decreased from CNY 10,075,848.53, indicating a decline of about 6.4%[121]. - Owner's equity increased to CNY 1,662,735,447.37 from CNY 1,644,893,026.76, representing a growth of approximately 1.1%[121]. - The company’s total liabilities were CNY 517,169,000 at the end of the reporting period[145]. Product and Market Focus - The proportion of revenue from the injectable nerve growth factor product, Jinlujie, remains high, indicating significant reliance on a single product[5]. - The main product of the company is Jinlujie, an injectable mouse nerve growth factor, which has been widely applied in various fields of nerve injury repair[29]. - Jinlujie was included in the National Medical Insurance Category B in 2009, indicating its recognized therapeutic value and market acceptance[30]. - The competitive landscape for Jinlujie includes four manufacturers, with a tight market share among Jinlujie, Su Taishen, and Enjingfu[33]. - The company faces risks related to heavy reliance on a single product, specifically the injection of mouse nerve growth factor, which constitutes a significant portion of revenue[64]. Research and Development - The company plans to focus on the research and development of biological innovative drugs in the coming years[8]. - The company's in-progress projects include recombinant human nerve growth factor and thymopentin, enhancing its R&D capabilities through both independent and collaborative efforts[31]. - The company emphasizes the importance of technological innovation and product development, focusing on biopharmaceutical innovation in the coming years[66]. - The company adheres to a combined research and development model of independent and collaborative efforts to continuously innovate and revitalize its product offerings[66]. Financial Management and Investments - The total amount of raised funds is RMB 79,747.59 million, with RMB 985.02 million invested during the reporting period[52]. - The cumulative amount of raised funds invested is RMB 2,881.03 million, with no changes in the use of raised funds[52]. - The company has entrusted financial management with a total amount of RMB 70,600 million, including RMB 24,000 million from idle raised funds[59]. - The company has provided a loan of RMB 5,900 million to Beijing Shadong Biotechnology Co., Ltd. at an interest rate of 4.75%[61]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,837[98]. - The largest shareholder, Wuhan Sanjiangyuan Investment Development Co., Ltd., holds 38.70% of shares, totaling 40,000,000 shares[98]. - The second-largest shareholder, Chen Ya, holds 9.48% of shares, totaling 9,800,000 shares[98]. Compliance and Governance - The financial report for the half-year period was not audited[112]. - The financial statements have been approved by the board of directors on August 24, 2018, ensuring compliance with accounting standards[149]. - The company maintains a continuous operating capability for at least 12 months following the reporting period[152]. Cash Flow and Investment Activities - The company generated CNY 315,253,987.20 in cash from operating activities, compared to CNY 392,882,317.86 in the previous period, a decrease of about 19.7%[130]. - Total cash inflow from investment activities was ¥106,938,561.46, significantly higher than ¥22,850,684.47 in the previous year[132]. - The net cash flow from investment activities was ¥-803,968.83, improving from ¥-10,043,308.52 in the previous year[132]. - The net cash flow from financing activities was ¥-25,037,518.51, reflecting a decrease in cash inflow compared to the previous year[132]. Inventory and Receivables Management - Accounts receivable decreased to ¥208.99 million from ¥234.21 million, reflecting a reduction of approximately 10.73%[114]. - Inventory increased to ¥28.43 million from ¥22.45 million, representing a growth of approximately 26.67%[114]. - The company applies an aging analysis method for bad debt provision, with a 5% provision for accounts receivable within 1 year and 100% for those over 5 years[183]. - The company measures inventory at the lower of cost and net realizable value, recognizing impairment losses when necessary[186].
海特生物(300683) - 2018 Q1 - 季度财报
2018-04-25 16:00
Financial Performance - Total revenue for Q1 2018 was ¥131,749,849.30, a decrease of 22.45% compared to ¥169,881,516.59 in the same period last year[8] - Net profit attributable to shareholders was ¥23,743,408.83, down 23.13% from ¥30,889,740.45 year-on-year[8] - Net profit after deducting non-recurring gains and losses was ¥20,367,165.19, a decline of 32.30% compared to ¥30,085,553.86 in the previous year[8] - Basic and diluted earnings per share were both ¥0.23, representing a decrease of 42.50% from ¥0.4 in the previous year[8] - The weighted average return on equity was 1.44%, down 2.90% from 4.34% in the same period last year[8] - The company reported a total comprehensive income attributable to the parent company of CNY 23,743,408.83, a decrease of 23.5% from CNY 30,889,740.45 in the previous year[44] - The total operating profit for Q1 2018 was CNY 29,754,738.46, a decrease of 18.9% from CNY 36,641,367.15 in Q1 2017[44] - The net profit for Q1 2018 was CNY 25,140,048.02, down 20.5% from CNY 31,700,835.89 in Q1 2017[44] Cash Flow and Liquidity - Operating cash flow for the period was ¥26,363,112.43, a significant increase of 300.84% from a negative cash flow of ¥13,126,138.98 in the same period last year[8] - The net cash flow from operating activities was ¥27,327,103.48, a significant improvement from the previous period's loss of ¥11,692,541.73[52] - Total cash inflow from operating activities was ¥167,776,917.92, down 11.4% from ¥189,372,325.72 in the previous period[52] - Cash outflow from operating activities totaled ¥140,449,814.44, a decrease of 30.2% compared to ¥201,064,867.45 in the previous period[52] - Cash and cash equivalents decreased by 32.78% from CNY 697,582,253.49 to CNY 468,900,516.85, primarily due to increased investments in financial products[20] - Cash and cash equivalents at the end of the period were ¥442,182,628.04, up from ¥365,842,426.26 in the previous period[53] - The company reported a net cash outflow from investing activities of CNY 260,959,551.45, compared to a net outflow of CNY 214,744,381.02 in Q1 2017[49] Investments and Projects - The company plans to expand its product line into traditional Chinese medicine and in vitro diagnostic reagents to create new profit growth points[11] - The company emphasizes innovation in drug development and aims to focus on biopharmaceuticals in the coming years, while also enhancing its existing products[13] - Total raised funds amounted to 79,747.59 million yuan, with 620.52 million yuan invested in the current quarter[24] - Cumulative investment from raised funds reached 2,516.53 million yuan[24] - The biological engineering drug comprehensive formulation base upgrade project has a total investment commitment of 22,000 million yuan, with 606.98 million yuan invested, achieving a progress rate of 4.31%[24] - The R&D center and laboratory construction project has a total investment commitment of 38,030 million yuan, with 13.54 million yuan invested, achieving a progress rate of 4.09%[24] - The marketing service network upgrade project has a total investment commitment of 10,188 million yuan, with no funds invested yet, achieving a progress rate of 0.13%[24] Asset Management - Cash and cash equivalents at the end of the period were 468,900,516.85 yuan, down from 697,582,253.49 yuan at the beginning of the period[31] - Total assets at the end of the period were 1,902,780,947.85 yuan, down from 1,908,751,901.97 yuan at the beginning of the period[32] - Total non-current assets increased from 159,876,663.66 yuan to 164,482,699.61 yuan[32] - Accounts receivable decreased by 73.11% from CNY 32,376,477.98 to CNY 8,705,857.39, mainly due to the settlement of receivables during the period[20] - Employee compensation payable decreased by 48.16% from CNY 8,124,254.03 to CNY 4,211,481.12, reflecting the payment of previously accrued salaries[20] - The company reported a significant increase in asset impairment losses by 529.53%, from CNY -344,517.21 to CNY 1,479,814.47, due to increased provisions for receivables[20] Market and Strategic Focus - The company is heavily reliant on the product Jinlujie, which accounted for a significant portion of revenue, posing a risk if market conditions change[11] - The company aims to launch new products and improve service efficiency to mitigate adverse market conditions[21] - The company plans to continue focusing on the biopharmaceutical market, emphasizing R&D and optimizing product structure to enhance core competitiveness[21]
海特生物(300683) - 2017 Q4 - 年度财报
2018-04-08 16:00
Financial Performance - The company's operating revenue for 2017 was ¥750,258,800.06, a decrease of 2.69% compared to ¥770,974,124.20 in 2016[20] - The net profit attributable to shareholders for 2017 was ¥142,389,649.91, down 9.34% from ¥157,053,448.93 in 2016[20] - The net profit after deducting non-recurring gains and losses was ¥124,548,584.96, a decline of 15.95% from ¥148,181,032.44 in 2016[20] - The net cash flow from operating activities decreased by 42.25% to ¥83,076,511.58 from ¥143,859,871.49 in 2016[20] - The basic earnings per share for 2017 were ¥1.65, down 18.72% from ¥2.03 in 2016[20] - The weighted average return on equity for 2017 was 13.77%, a decrease of 9.85% from 23.62% in 2016[20] - The company achieved a consolidated operating revenue of 750,258,800.06 yuan and a net profit attributable to shareholders of 142,389,649.91 yuan in 2017[31] - The company reported a total operating cost of CNY 33.02 million, a decrease of 3.04% from the previous year[53] - Net profit for the period was CNY 141,197,434.18, down from CNY 156,735,440.05 in the previous period, representing a decrease of approximately 9.5%[196] - Earnings per share decreased to CNY 1.65 from CNY 2.03, reflecting a decline in profitability[197] Assets and Liabilities - The total assets at the end of 2017 were ¥1,908,751,901.97, an increase of 83.67% from ¥1,039,220,473.03 at the end of 2016[20] - Total current assets increased to ¥1,748,875,238.31 from ¥896,103,863.97, representing a growth of approximately 95.5%[187] - Total liabilities decreased to ¥265,624,580.99 from ¥335,866,440.63, a reduction of about 20.9%[189] - Total equity increased significantly to ¥1,643,127,320.98 from ¥703,354,032.40, representing a growth of approximately 133.4%[190] - The company's retained earnings rose to ¥490,191,342.58 from ¥362,307,731.50, an increase of about 35.3%[190] Research and Development - The company plans to focus on new drug research and development, emphasizing technological innovation and product development[8] - The company has established a dual research and development model combining independent and collaborative efforts, enhancing its innovation capabilities[33] - The company’s R&D projects include the development of recombinant human nerve growth factor and other innovative drugs, indicating a commitment to expanding its product portfolio[33] - The company has made significant progress in R&D, including breakthroughs in rhNGF expression technology and the development of a rare disease drug project[42] - The total R&D investment for 2017 was ¥24,497,690.88, accounting for 3.27% of operating revenue[63] - The number of R&D personnel increased to 60 in 2017, representing 21.66% of the total workforce[63] Market and Competition - The company operates in a competitive market with four main producers of nerve growth factor products, maintaining a duopoly with its main competitors[35] - The biopharmaceutical industry in China is experiencing rapid growth, with a revenue increase of 13.95% year-on-year in 2014, reaching 275 billion yuan[35] - The company has been recognized for its product's efficacy in treating various neurological conditions, leading to its inclusion in the national medical insurance catalog[32] - The company’s main product, Jinlujie, has established a good reputation and brand recognition, contributing to its market leadership[38] Cash Flow and Investments - Operating cash inflow for 2017 was ¥778,395,436.42, a year-on-year increase of 4.20%[66] - Investment cash inflow surged by 1,280.14% to ¥780,600,466.73, primarily due to increased recovery of maturing financial products[66] - The net cash flow from investment activities was -¥792,954,306.59, a significant decline of 3,960.40%[66] - Financing cash inflow reached ¥799,475,854.40, marking a dramatic increase of 9,893.45% due to the successful public offering[66] Corporate Governance - The company has a diverse board with members holding various academic and professional qualifications, including a PhD in management and a master's degree in accounting[145][146] - The board includes independent directors with extensive experience in finance and management, enhancing corporate governance[145][148] - The company has established a strict external guarantee system, ensuring no guarantees for the controlling shareholder or related parties[161] - The company has a complete governance structure in compliance with relevant laws and regulations, with no significant discrepancies from the guidelines issued by the China Securities Regulatory Commission[160] Future Outlook - Future outlook includes potential market expansion and new product development initiatives to drive growth[186] - The company is actively pursuing collaborations and investments in innovative projects, including a partnership with Beijing Shadong Biotechnology Co., Ltd. for new drug development[43] - Overall, the company remains optimistic about future growth, citing strong demand in existing markets[200]
海特生物(300683) - 2017 Q3 - 季度财报
2017-10-25 16:00
武汉海特生物制药股份有限公司 2017 年第三季度报告全文 武汉海特生物制药股份有限公司 2017 年第三季度报告 2017-019 2017 年 10 月 1 武汉海特生物制药股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈亚、主管会计工作负责人夏汉珍及会计机构负责人(会计主管 人员)羡雯声明:保证季度报告中财务报表的真实、准确、完整。 2 武汉海特生物制药股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产(元) | 1,878,611,807.53 | 1,039,220,473.03 | | 80.77% | | 归属于上市公司股东的净资 ...
海特生物(300683) - 2017 Q2 - 季度财报
2017-08-21 16:00
Financial Performance - Total revenue for the reporting period was CNY 388,631,216.97, an increase of 16.92% compared to CNY 332,392,590.89 in the same period last year[25]. - Net profit attributable to shareholders was CNY 69,538,620.03, reflecting a growth of 13.12% from CNY 61,473,079.01 year-over-year[25]. - Net profit after deducting non-recurring gains and losses was CNY 65,533,661.52, up 15.60% from CNY 56,688,119.39 in the previous year[25]. - The net cash flow from operating activities reached CNY 46,611,091.58, representing a 16.32% increase from CNY 40,070,434.85 in the same period last year[25]. - Basic and diluted earnings per share were both CNY 0.9, an increase of 13.92% compared to CNY 0.79 in the previous year[25]. - Total assets at the end of the reporting period were CNY 1,086,395,718.05, a growth of 4.54% from CNY 1,039,220,473.03 at the end of the previous year[25]. - Net assets attributable to shareholders increased to CNY 766,362,750.49, up 9.98% from CNY 696,824,130.46 at the end of the previous year[25]. - The company achieved total revenue of ¥388,631,216.97, representing a year-on-year growth of 16.37%[52]. - The net profit attributable to shareholders was ¥68,875,131.49, reflecting a year-on-year increase of 12%[52]. Product and Market Position - The sales revenue of the injection product Jinlujie reached ¥386,706,364.76, accounting for 99.5% of the company's total operating income during the reporting period[6]. - The market for nerve injury repair drugs is rapidly expanding, with Jinlujie positioned in a growth phase, but faces significant competition from other similar products[7]. - The company’s main products include Jinlujie, Aogantide, and Thrombin, which are used in various therapeutic areas including nerve repair and hepatitis treatment[32][34][35]. - The company is focused on the research and development of innovative biopharmaceuticals, including the leading product, Jinlujie, which is a first-in-class nerve growth factor[32][33]. - The company plans to accelerate the development of new products and enhance marketing efforts for over 20 other products, including hepatitis B treatment drug Aogantide and hemostatic agent Thrombin, to create new profit growth points[78]. Risks and Challenges - The company faces risks related to the reliance on a single product, as any significant changes in the operating environment of Jinlujie could adversely affect financial performance[6]. - The company is exposed to market risks due to the cancellation of government pricing for drugs, which may lead to price declines and impact revenue and profit[12]. - The company acknowledges the risk of losing core technical personnel, which is crucial for maintaining its technological advantage in the industry[10]. - The effective component of Jinlujie is derived from mouse submandibular gland, which carries potential risks related to undiscovered viruses during production[9]. - The company operates in a competitive environment where other nerve growth factor products may gain market share, posing a risk to Jinlujie's sales[7]. Research and Development - The company emphasizes the importance of technological innovation and plans to focus on the research and development of biological innovative drugs in the coming years[10]. - The company is committed to developing new products but acknowledges the lengthy and unpredictable nature of the drug development process[10]. - The company has established a strategic partnership for collaborative research and development with Chongqing Paijin Biotechnology Co., Ltd. since June 2013[38]. - The company is focused on R&D and has established partnerships with institutions like Huazhong University of Science and Technology for innovation[49]. Financial Management and Strategy - The company does not plan to distribute cash dividends or issue bonus shares[13]. - The company is committed to enhancing its internal control management and talent development strategies[55][56]. - The company has provided a loan of ¥43 million to Beijing Shadong Biotechnology Co., Ltd. at an interest rate of 4.75% for research and operations[73]. - The total amount of entrusted financial management was ¥210 million, with a return of ¥2.85 million from financial products[69]. - The company reported no significant asset or equity sales during the reporting period[74]. Employee and Operational Insights - The company has a workforce of 290 employees, with 75.86% holding a college degree or higher[44]. - The company reported a decrease in employee compensation payable to CNY 4,409,648.64 from CNY 5,912,246.22, a reduction of approximately 25.4%[136]. - The cash outflow for employee payments was CNY 20,788,643.69, up from CNY 17,430,357.01, indicating a rise of 13.6%[147]. Asset and Liability Management - The company's cash and cash equivalents increased to ¥644,551,977.16 from ¥607,984,194.10, representing a growth of approximately 6.5%[129]. - Accounts receivable rose to ¥236,007,196.60 from ¥217,695,985.18, indicating an increase of about 8.5%[129]. - Inventory increased to ¥16,457,394.28 from ¥14,989,590.25, reflecting a growth of approximately 9.8%[129]. - Total liabilities decreased to CNY 313,214,089.24 from CNY 333,818,330.13, reflecting a reduction of approximately 6.2%[136]. - Owner's equity increased to CNY 773,348,774.96 from CNY 702,356,784.07, showing a growth of around 10.1%[136]. Compliance and Reporting - The financial report for the first half of the year was not audited[127]. - The company adheres to the Chinese Accounting Standards, ensuring that the financial statements accurately reflect its financial position and operating results[174]. - The company prepares consolidated financial statements based on the financial reports of itself and its subsidiaries, reflecting the overall financial status of the group[182].